These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11601112)

  • 1. [Inhibition of the renin-angiotensin system in type 2 diabetes. New significant results concerning type 2 diabetes and renal disease].
    Mogensen CE
    Ugeskr Laeger; 2001 Oct; 163(40):5488. PubMed ID: 11601112
    [No Abstract]   [Full Text] [Related]  

  • 2. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
    Nilsson P; Attvall S
    Lakartidningen; 2001 Nov; 98(45):4960-2. PubMed ID: 11816896
    [No Abstract]   [Full Text] [Related]  

  • 5. [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
    Arner P
    Lakartidningen; 2002 Jan; 99(1-2):80-2. PubMed ID: 11871182
    [No Abstract]   [Full Text] [Related]  

  • 6. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney disease in diabetology: lessons from 2008.
    Schernthaner G
    Nephrol Dial Transplant; 2009 Feb; 24(2):396-9. PubMed ID: 19144896
    [No Abstract]   [Full Text] [Related]  

  • 12. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring.
    Rossing K
    Dan Med Bull; 2007 May; 54(2):79-98. PubMed ID: 17521525
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R; Brown DL
    Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Microalbuminuria is an early marker for increased morbidity and mortality].
    Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
    Fortschr Med Orig; 2003 Feb; 121 Suppl 1():28-32. PubMed ID: 14732947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus.
    Rosner MH; Okusa MD
    Arch Intern Med; 2003 May; 163(9):1025-9. PubMed ID: 12742799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
    Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prediction, screening and treatment of renal complications of diabetes].
    Marre M; Larger E
    Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.